Hyundai Motor Co. will launch its Elantra Avante N Line compact model with a 1.6-liter gasoline turbocharged engine in South Korea later this month as it strives to boost sales.
The Avante N Line doles out 204 horsepower and is available in variants of six-speed manual transmission or a seven-speed double-clutch transmission.
According to Executive Vice President Thomas Schemera, who is in charge of Hyundai Motor Group's product division, the attractively priced new model features a more aggressive design with N Line's signature red accents.
The Elantra Avante N Line comes with a motorsport-patterned air intake, the company's signature cascading grille, larger brakes, and 18-inch alloy wheels.
Hyundai's N Line, which sits its N brand and the general Hyundai brand, brings performance-inspired elements to base model vehicles.


Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Instagram Outage Disrupts Thousands of U.S. Users
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 



